A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-related adverse events based on the US Food a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Huqun Li (Egilea), Chongshu Wang (Egilea), Aiping Deng (Egilea), Cuilian Guo (Egilea)
Formatua: Liburua
Argitaratua: Frontiers Media S.A., 2023-12-01T00:00:00Z.
Gaiak:
Sarrera elektronikoa:Connect to this object online.
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

Connect to this object online.

3rd Floor Main Library

Aleari buruzko argibideak 3rd Floor Main Library
Sailkapena: A1234.567
Alea 1 Eskuragarri